In this double-blind, randomized, parallel, placebo-controlled clinical trial, supplementation with 1200 mg ALA after eight weeks resulted in a substantial reduction in ox-LDL and Lp-PLA2 mass and improvement in Lp-PLA2 distribution between HDL and apoB-containing lipoproteins in type 2 diabetic patients. The gene discussed is PLA2G7; the disease is type 2 diabetes mellitus.